Skip to main content

monoclonal antibodies Archives

Technique hastens COVID-19 antibody discovery

Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.

Read more


COVID-19: two years of challenges, lessons, victories

Mar. 3, 2022—Two years ago this week, the cataclysmic coronavirus known as SARS-CoV-2 arrived in Middle Tennessee.

Read more


Pandemic leads to broader use of monoclonal antibodies

Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.

Read more


Omicron evades some but not all monoclonal antibodies: study

Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.

Read more


Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.

Read more


Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

Dec. 2, 2021—  by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...

Read more


Zost honored for research on COVID-19, other life-threatening viral diseases

Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. 

Read more


“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Read more


VUMC antibodies help neutralize two deadly viruses: study

Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.

Read more


COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.

Read more


Team isolates antibodies that target alphaviruses

Aug. 19, 2021—A multi-institutional team led by researchers at Vanderbilt University Medical Center has isolated monoclonal antibodies that in laboratory and animal studies prevented infection by alphaviruses, including the often-lethal Eastern equine encephalitis virus (EEEV).

Read more


Combination antibody therapies should retain effectiveness against emerging COVID-19 variants: study

Jun. 22, 2021—Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more